Remimazolam
CAS No. 308242-62-8
Remimazolam ( CNS-7056,CNS 7056,CNS7056 )
Catalog No. M22876 CAS No. 308242-62-8
Remimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 357 | In Stock |
|
10MG | 596 | In Stock |
|
25MG | 882 | In Stock |
|
50MG | Get Quote | In Stock |
|
100MG | Get Quote | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRemimazolam
-
NoteResearch use only, not for human use.
-
Brief DescriptionRemimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?
-
DescriptionRemimazolam is a benzodiazepine derivative drug as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures.?Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.?Mice showed significantly increased time to movement outside a set perimeter after 5-minute exposure to increasing concentrations (10-25 mg/mL solutions) of inhaled remimazolam aerosols.?Differences in mean (95% confidence interval) time to movement from pretest baseline group (0.05 [0.01-0.09] minutes) were 11 (4-18), 15 (5-26), 30 (19-41), and 109 (103-115) minutes after exposure to remimazolam aerosol of 10, 15, 20, and 25 mg/mL, respectively (P = .007 - P .0001).?Exposure of rats to remimazolam aerosols alone failed to produce sedation or analgesia after a 5-minute exposure.?When remimazolam (10 or 25 mg/mL) was administered in combination with 250 μg/mL remifentanil, there was a significant difference in time to tail flick (P .0001) consistent with a strong analgesic effect.?Mean (95% confidence interval) differences in time to tail flick from the pretest baseline group (3.2 [2.5-3.9] seconds) were 14 (10-18) seconds when 250 μg/mL remifentanil was administered with either 10 or 25 mg/mL remimazolam.?Remimazolam alone or in combination with remifentanil did not cause lung irritation, bronchospasm, or other adverse pulmonary events to the respiratory tract of mice as assessed by Flexi-Vent pulmonary function tests.?Remimazolam can significantly potentiate the analgesic effect of remifentanil when concurrently delivered via inhalation.
-
SynonymsCNS-7056,CNS 7056,CNS7056
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Areanervous system
-
IndicationAnesthesia
Chemical Information
-
CAS Number308242-62-8
-
Formula Weight439.31
-
Molecular FormulaC21H19BrN4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:Soluble; Water:Insoluble
-
SMILESCC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rower, Joseph, Sakata, et al. Inhaled Remimazolam Potentiates Inhaled Remifentanil in Rodents[J]. Anesthesia and Analgesia: Journal of the International Anesthesia Research Society, 2017.
molnova catalog
related products
-
Pseudolaric Acid C
Pseudolaric Acid C has weak antifungal activity against Candida albicans.
-
Ecamsule
Ecamsule is a benzylidene camphor derivative, many of which are known for their excellent photostability.
-
Scopine HCl
Scopine HCl salt is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.